<DOC>
	<DOCNO>NCT02512562</DOCNO>
	<brief_summary>This open-label , two-group , fixed-sequence study evaluate effect ACH-3102 Simeprevir AL-335 pharmacokinetics healthy volunteer .</brief_summary>
	<brief_title>A Study Evaluate Effect ACH-3102 Simeprevir AL-335 Pharmacokinetics Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>1 . Subject provide write consent . 2 . In investigator 's opinion , subject able understand comply protocol requirement , instruction , protocolstated restriction likely complete study plan . 3 . Subject good health deem investigator , base finding medical evaluation include medical history , physical examination , laboratory test ECG . 4 . Male female , 1860 year age . 5 . Body mass index ( BMI ) 1832 kg/m2 , inclusive . The minimum weight 50 kg . No 25 % subject may enrol BMI â‰¥ 30 kg/m2 . 6 . A female subject eligible participate study nonchildbearing potential ( defined female document tubal ligation , bilateral oophorectomy hysterectomy ) postmenopausal ( defined 12 month spontaneous amenorrhea follicle stimulate hormone ( FSH ) level within laboratory 's reference range postmenopausal female ) ) . A postmenopausal female receive hormone replacement therapy willing discontinue hormone therapy 28 day study drug dose agrees remain hormone replacement therapy duration study may eligible study participation . 7 . If male , subject surgically sterile practice specific form birth control 6 month end study . Males must agree refrain sperm donation checkin 6 month dose . 8 . Willing avoid prolonged sun exposure take SMV followup . Subjects also advise use broad spectrum sun screen lip balm least sun protection factor ( SPF ) &gt; 30 help protect potential sunburn . 1 . Pregnant nursing ( lactate ) female , confirm positive HCG laboratory test female contemplate pregnancy . Men whose female partner pregnant contemplate pregnancy date screen 6 month last dose study drug . 2 . Clinically significant cardiovascular , respiratory , renal , gastrointestinal , hematologic , neurologic , thyroid medical illness psychiatric disorder , determine Investigator and/or Sponsor 's Medical Monitor . 3 . Positive screen test hepatitis B , C HIV serology . Subjects previously infect HCV achieve sustained virologic response treatment ( detectable HCV RNA 6 month post treatment ) eligible . 4 . Any condition , opinion investigator , would compromise study 's objective wellbeing subject prevent subject meeting study requirement . 5 . Participation investigational drug trial receive investigational vaccine within 30 day 5 halflives ( whichever longer ) prior study medication . 6 . Clinically significant abnormal ECG finding . Particularly , history family history prolong QT syndrome ( e.g. , torsade de pointes ) sudden cardiac death . 7 . ECG PR &gt; 200 m , QRS &gt; 120 m , QTcF &gt; 450 m , assess centrally read 12 lead ECG screen visit . 8 . Clinically significant blood loss elective blood donation significant volume ( i.e. , &gt; 500 mL ) within 60 day first dose study drug ; &gt; 1 unit plasma within 7 day first dose study drug . 9 . Abnormal heart rate , respiratory rate , temperature blood pressure value outside normal range ( evaluated semirecumbent recumbent position 5 minute rest ) . One repeat measurement additional 5 minute rest permit . 10 . Evidence active infection . 11 . Unwilling abstain alcohol least 1 week prior start dose study completion visit . 12 . History regular alcohol intake &gt; 7 unit per week alcohol female &gt; 14 unit per week male ( one unit define 10 g alcohol ) within 3 month screen visit . 13 . History tobacco use use nicotinecontaining product within 3 month screen visit . 14 . The subject positive prestudy drug screen . 15 . The use concomitant medication , include prescription , counter medication , herbal medication , inducer inhibitor CYP450 enzymes drug transporter ( include Pgp ) within 14 day prior first dose study medication exclude , unless approve Sponsor 's Medical Monitor . Occasional use acetaminophen permit . 16 . Exposure four new investigational entity within 12 month prior first dose day . 17 . Hypersensitivity active substance excipients AL335 , ACH3102 SMV . 18 . Subjects East Asian ancestry . 19 . Abnormal biochemistry hematology laboratory result obtain screen . Elevated bilirubin subject suspect Gilbert 's disease allow . 20 . Unwillingness inability comply study protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>